Your browser doesn't support javascript.
loading
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Cohen, Jeffrey A; Comi, Giancarlo; Arnold, Douglas L; Bar-Or, Amit; Selmaj, Krzysztof W; Steinman, Lawrence; Havrdová, Eva K; Cree, Bruce Ac; Montalbán, Xavier; Hartung, Hans-Peter; Huang, Vivian; Frohna, Paul; Skolnick, Brett E; Kappos, Ludwig.
Afiliação
  • Cohen JA; Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
  • Comi G; Department of Neurology, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Arnold DL; NeuroRx Research and Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
  • Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Selmaj KW; Center for Neurology, Lódz, Poland.
  • Steinman L; Department of Neurology & Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, USA.
  • Havrdová EK; Department of Neurology and Center for Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Cree BA; UCSF Weill Institute for Neurosciences and Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
  • Montalbán X; Division of Neurology and St. Michael's Hospital, University of Toronto, Toronto, ON, Canada/Cemcat, Vall d'Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Hartung HP; Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
  • Huang V; Biostatistics, Celgene Corporation, San Diego, CA, USA.
  • Frohna P; Clinical Development, Celgene Corporation, San Diego, CA, USA.
  • Skolnick BE; Clinical Development, Celgene Corporation, San Diego, CA, USA.
  • Kappos L; Neurologic Clinic and Polyclinic, University Hospital of Basel and University of Basel, Basel, Switzerland.
Mult Scler ; 25(9): 1255-1262, 2019 08.
Article em En | MEDLINE | ID: mdl-30043658
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxidiazóis / Avaliação de Resultados em Cuidados de Saúde / Esclerose Múltipla Recidivante-Remitente / Moduladores do Receptor de Esfingosina 1 Fosfato / Indanos Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxidiazóis / Avaliação de Resultados em Cuidados de Saúde / Esclerose Múltipla Recidivante-Remitente / Moduladores do Receptor de Esfingosina 1 Fosfato / Indanos Idioma: En Ano de publicação: 2019 Tipo de documento: Article